We envision a world where no woman loses her life to cervical cancer due to a lack of early detection. CerviHope is committed to making advanced medical technology accessible, affordable, and impactful in regions with limited healthcare infrastructure.

• Advanced AI Technology: Our machine learning model, trained on diverse datasets, identifies early signs of cervical cancer with an accuracy of over 99%. This ensures reliable and timely diagnoses, empowering healthcare providers and patients alike.

• Accessibility First: Unlike traditional methods that require expensive laboratory infrastructure and trained personnel, CerviHope's solution is portable and user-friendly. Designed to function even in remote areas, it offers a practical solution for regions with minimal healthcare facilities.

• Affordability: By eliminating the dependency on costly lab equipment, CerviHope drastically reduces the cost of screening, making it viable for implementation in low-resource settings.

• Scalable and Adaptable: Our solution is designed to scale globally while adapting to local healthcare environments. From rural villages to urban clinics, CerviHope integrates seamlessly to address diverse healthcare challenges.

Every year, over 300,000 women lose their lives to cervical cancer, with 90% of these deaths occurring in low- and middle-income countries. The barriers are numerous:

• Limited Access: Women in rural and underserved areas often lack access to basic screening facilities.

• Cost Prohibitions: High costs associated with traditional diagnostic methods prevent widespread adoption.

• Awareness Gap: Cultural stigma and lack of awareness delay early diagnosis, resulting in advanced-stage detection when treatment options are limited.

CerviHope tackles these barriers head-on by offering an all-in-one diagnostic platform that combines affordability, efficiency, and accessibility. Our mission is to create equity in healthcare, ensuring every woman, regardless of her background, has the opportunity for a timely and accurate diagnosis.

At CerviHope, we bring together cutting-edge technology and a human-centered design philosophy:

• Empowering Communities: We work with local healthcare workers to train and equip them with tools to carry out screenings effectively.

• Data-Driven Insights: Our platform not only diagnoses but also collects anonymized data to track health trends, enabling informed public health interventions.

• Sustainable Impact: By reducing dependency on external resources, CerviHope establishes a sustainable model for cervical cancer screening worldwide.

We are Adya (17) and Arya Bharadwaj (15), siblings with a shared passion for using technology to create meaningful change. Adya developed the AI model that powers CerviHope, while Arya designed the intuitive platform that brings this innovation to life. Together, we are committed to making cervical cancer detection more efficient, accessible, and impactful.

Cervical cancer is the fourth most common cancer among women, yet it is preventable and treatable if detected early. Despite advancements in medical technology, over 300,000 women die annually from cervical cancer, with 90% of deaths occurring in low- and middle-income countries. This disproportionate mortality is driven by several systemic barriers:

1. Lack of Access to Screening:

   • In rural and underserved regions, healthcare infrastructure is often insufficient to support routine cervical cancer screenings.

   • Many areas lack specialized personnel to conduct pap smear tests or analyze results, leaving women without options for early detection.

2. High Cost of Traditional Methods:

   • Conventional pap smear and HPV testing require laboratory equipment and highly trained technicians, which are expensive and inaccessible to resource-constrained healthcare systems.

   • Women from low-income backgrounds are disproportionately affected as they are unable to afford these diagnostic services.

3. Late-Stage Diagnosis:

   • In many cases, cervical cancer is diagnosed in its advanced stages due to the absence of regular screening programs and awareness campaigns.

   • Delayed diagnosis drastically reduces survival rates, as treatment options for late-stage cervical cancer are limited and costly.

4. Cultural and Social Barriers:

   • In several regions, the cultural stigma surrounding gynecological health discourages women from seeking preventive care.

   • Misconceptions about cervical cancer and limited education on its symptoms exacerbate the delay in seeking a diagnosis.

The burden of cervical cancer is particularly acute in countries with limited healthcare resources:

1. • Sub-Saharan Africa: The region faces the highest cervical cancer mortality rate, with 34 deaths per 100,000 women annually.

   • South Asia: Millions of women are at risk due to insufficient access to reliable screening tools and healthcare infrastructure.

   • Rural Communities Worldwide: Even in middle-income countries, rural areas are underserved, leading to significant healthcare inequities.

Existing cervical cancer detection methods, while effective in controlled environments, are:

1. • Inaccessible to rural areas due to logistical challenges and infrastructure requirements.

   • Costly, making them unaffordable for mass implementation in low-resource settings.

   • Time-consuming, as traditional testing involves multiple visits for sample collection, processing, and follow-up.

CerviHope addresses these critical issues by providing an affordable, portable, and highly accurate diagnostic tool designed to overcome these systemic challenges. By focusing on early detection and accessibility, CerviHope aims to save lives and reduce the global burden of cervical cancer.